These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15170907)

  • 61. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
    Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
    Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
    [No Abstract]   [Full Text] [Related]  

  • 62. [Redefining treatment of rheumatic arthritis with anti-cytokines].
    Gabay C; So A
    Rev Med Suisse; 2007 Mar; 3(103):715-7. PubMed ID: 17458148
    [No Abstract]   [Full Text] [Related]  

  • 63. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al.
    Saxne T; Larsson L; Geborek P
    Arthritis Rheum; 2004 Sep; 50(9):3049-50; author reply 3050-1. PubMed ID: 15457477
    [No Abstract]   [Full Text] [Related]  

  • 64. Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis.
    Gonzalez-Gay MA; Garcia-Unzueta MT; Berja A; Vazquez-Rodriguez TR; Gonzalez-Juanatey C; de Matias JM; Martin J; Dessein PH; Llorca J
    Ann Rheum Dis; 2008 Nov; 67(11):1644-6. PubMed ID: 18854515
    [No Abstract]   [Full Text] [Related]  

  • 65. Magnetic resonance imaging in rheumatologic practice: low field or standard.
    Sharp JT
    J Rheumatol; 2006 Oct; 33(10):1925-7. PubMed ID: 17014009
    [No Abstract]   [Full Text] [Related]  

  • 66. Tumor necrosis factor alpha inhibitors and methotrexate: implications for deployed personnel.
    Martin JJ
    Aviat Space Environ Med; 2005 Dec; 76(12):1162-6. PubMed ID: 16370267
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis.
    Choy E
    Cytokine; 2004 Nov 21-Dec 7; 28(4-5):158-61. PubMed ID: 15588689
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Monoclonal antibodies in rheumatic diseases.
    Yuvienco C; Schwartz S
    Med Health R I; 2011 Nov; 94(11):320-4. PubMed ID: 22204094
    [No Abstract]   [Full Text] [Related]  

  • 69. Anti-tuberculosis treatment and infliximab.
    Wallis RS
    Respir Med; 2005 Dec; 99(12):1620-2. PubMed ID: 16039841
    [No Abstract]   [Full Text] [Related]  

  • 70. Proceedings from the XIth International Symposium on Advances in Targeted Therapies, 22 to 26 April 2009.
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i1-99. PubMed ID: 20310079
    [No Abstract]   [Full Text] [Related]  

  • 71. Update in rheumatology: evidence published in 2011.
    Forbess LJ; Bass AR
    Ann Intern Med; 2012 Jul; 157(2):114-9. PubMed ID: 22801673
    [No Abstract]   [Full Text] [Related]  

  • 72. Novel immunological targets in rheumatic diseases: clues from current therapies.
    D'Acquisto F; Rattazzi L; Piras G; Galuppo ML
    Drug Discov Today; 2014 Aug; 19(8):1155-60. PubMed ID: 24984284
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immunology: Zoster vaccine and biologic agents: time to question a paradigm?
    Bongartz T; Orenstein R
    Nat Rev Rheumatol; 2012 Nov; 8(11):636-8. PubMed ID: 23027029
    [No Abstract]   [Full Text] [Related]  

  • 74. Advances in Targeted Therapies VI. Proceedings of the 6th International Symposium. Venice, Italy, 28 April-2 May 2004.
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2():ii1-101. PubMed ID: 15479863
    [No Abstract]   [Full Text] [Related]  

  • 75. Editorial: the vital role of randomized controlled trials in Arthritis & Rheumatology.
    Solomon DH; Weinblatt ME; Bucala RJ
    Arthritis Rheumatol; 2015 Oct; 67(10):2555-6. PubMed ID: 26139424
    [No Abstract]   [Full Text] [Related]  

  • 76. [Infections due to mycobacteria and anti-TNFalpha drugs].
    Regnier S; Caumes E
    Ann Dermatol Venereol; 2009 Nov; 136(11):763-5. PubMed ID: 19917427
    [No Abstract]   [Full Text] [Related]  

  • 77. The development of anticytokine therapeutics for rheumatic diseases.
    Arend WP; Goldring MB
    Arthritis Rheum; 2008 Feb; 58(2 Suppl):S102-9. PubMed ID: 18240200
    [No Abstract]   [Full Text] [Related]  

  • 78. Pregnancy appears difficult to obtain and TNF-alpha blockers cannot always be discontinued in women with rheumatic diseases.
    Gaujoux-Viala C; Eymard C; Dougados M; Gossec L
    Clin Exp Rheumatol; 2009; 27(6):1059. PubMed ID: 20149335
    [No Abstract]   [Full Text] [Related]  

  • 79. Anti-TNF agents inducing psoriasis: a recognized adverse effect.
    Scheinberg M; Gonçalves DP; Laurindo IM
    J Clin Rheumatol; 2008 Apr; 14(2):130. PubMed ID: 18391692
    [No Abstract]   [Full Text] [Related]  

  • 80. Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors.
    Mariette X; Reynolds AV; Emery P
    Ann Rheum Dis; 2012 Dec; 71(12):e2. PubMed ID: 23014259
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.